Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arena, Like Rivals, Greets Mixed Phase III Obesity Results With Brave Face

Executive Summary

Arena's release this week of surprisingly disappointing results for its obesity drug lorcaserin raises more questions about what "efficacy" means in the highly competitive space, and about the flexibility of FDA guidance for weight-management products

You may also be interested in...

Amylin And Takeda Team Up In Obesity

Two potentially important mid-stage programs in the obesity research space are off the partnering table with the announcement Nov. 1 that Takeda and Amylin have teamed up to develop and commercialize several obesity candidates, including pramlintide/metreleptin and davalintide

Amylin And Takeda Team Up In Obesity

Obesity research space is red hot, and now one of the key players has signed a big pharma partner; under the deal Amylin will get $75 million upfront.

Obesity Déjà Vu: Arena Airs More Mixed Phase III Data

Results raise doubts about prospects for regulatory approval and competitive positioning.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts